Cure trial momentum meets AI compute control shifts
The cure and capital race moved on three fronts today: globally there are 21,319 active cure-related trials, with 72 new Wire signals and 52 new Cure research updates arriving in the last 24 hours. On the infrastructure side of the AI phase transition, signals cluster around controlling inference and compute supply chains—Nvidia reportedly enters talks with Rebellions for Korean inference chips and also buys a minority stake in Cloverleaf Infrastructure, suggesting more deliberate routing of capacity. Meanwhile, the cure pipeline delivered concrete readouts, including BRII-179 ENRICH reporting 42.9% HBsAg loss at end of treatment, and an FDA-cleared blood test (PrecivityAD2) intended to aid evaluation for Alzheimer’s disease. The combined lesson is restrained: more trials and more signals keep compounding, but progress hinges on chokepoints—compute logistics today and validated therapeutics tomorrow. The window is still open.
Nvidia entered talks with Rebellions for Korean inference chips, suggesting a potential push for inference capacity outside dominant stacks.
If inference capacity shifts in supply, AI development and downstream biotech tooling gain faster throughput, shaping who can scale discovery and deployment across the cure race.
Watch whether the Nvidia–Rebellions talks and Nvidia’s Cloverleaf stake translate into concrete inference capacity, and treat next-quarter milestones as near-term proof points.